N/A N=9 rTMS and Botulinum Toxin in Primary Cervical Dystonia
Primary Cervical Dystonia · Dystonia
Primary: Dystonia Severity as Assessed by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 13; 17 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=516 Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) at the First On-treatment Visit (Week 4 or Week 12) — -3.8; -4.0; -3.8…
Phase 2 N=242 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in Observed Total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Score at Week 4 of Treatment Cycle 1 — 40.4; 41.5; 39.6; -10.3 Scores…
N/A N=8 Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study
Cervical Dystonia · Spasmodic Torticollis
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — -3.0; 0.25; -2.9; -1.5 units on a scale
Phase 4 N=10 Botox for Cervical Dystonia Following EMG Mapping
Cervical Dystonia
Primary: Pre- and Post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS)
N/A N=5 Dystonia Treatment With Injections Supplemented By Transcranial Magnetic Stimulation
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 17; 16.6; 17; 15.8 score on a scale — p=0.691
Phase 3 N=116 Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — -13.99; -5.23; 43.83; 45.81 points on a scale — p=<0.0001
N/A N=1,046 CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score — 27.1 score on a scale
Phase 2 N=61 A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
Cervical Dystonia
Primary: Number of Participants With Treatment-Related Serious Adverse Events — 0; 0; 0; 0 Participants
Phase 4 N=145 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia
Spasmodic Torticollis
Primary: Dysphagia Incidence Over 10 Weeks — 10; 12 Number of patients
Phase 3 N=108 Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
Cervical Dystonia
Primary: Change in Toronto Western Spasmodic Torticollis Rating Scale Total Score From Baseline — -16.21; 42.48; 25.81; -11.40 points on a scale
Phase 3 N=112 Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
Cervical Dystonia
Primary: TWSTRS Total Score at Week 4 and Week 12 for Treatment Cycles 1, 2 and 3. — 37.7; 30.1; 32.6; 27.0 units on a scale
Phase 2 N=16 Amlodipine Plus Botulinum Toxin for Focal Dystonia
Focal Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score — -6.00; -3.23 units on a scale
Phase 3 N=134 Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.
Cervical Dystonia
Primary: Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4. — 42.5; 42.4; 31.7; 39.9 units on a scale — p=<0.001
Phase 4 N=16 Neurotoxin and Physical Therapy
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 28; 20.1 total score on a scale
Phase 4 N=283 Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex
Cervical Dystonia
Primary: Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Severity Subscale Score Based on Blinded Rater Assessment at Week 4 After the 8th…
Phase 4 N=502 Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Cervical Dystonia
Primary: Treatment Assessment Scale (TAS), 4 Wks Post-injection Compared to Baseline (Time 0), Rating of Cervical Dystonia Symptoms — 0.9 points on a scale
Phase 3 N=233 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units)…
Phase 4 N=102 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia
Cervical Dystonia
Primary: Reduction of Total Tsui Score at 4 Weeks From Baseline — -3.98; -4.77 units on a scale — p=0.05
Phase 3 N=369 Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score Following First Treatment Cycle — -12.46; -13.99; -3.93 Units on a scale…
N/A N=48 A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
Cervical Dystonia · Blepharospasm
Primary: Dose of Botulinum Toxin Used to Treat Cervical Dystonia — 444.70; 536.30 units per patient per year
Phase 2 N=21 Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
Dystonia
Primary: Physician Global Perception of Change - Blinded Rater 1 — 1; 1; 1; 4 Participants
Phase 2 N=133 Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis
Cervical Dystonia · Spasmodic Torticollis
Primary: Mean Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Treatment — 3; 8.9; 7.6; 10.5 Points on a Scale
N/A N=20 rTMS in Spasmodic Dysphonia
Spasmodic Dysphonia · Laryngeal Dystonia
Primary: Adverse Response to rTMS — 0; 0 Participants
N/A N=6 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
Spasmodic Dysphonia · Laryngeal Dystonia · Deep Brain Stimulation
Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025
Phase 2 N=22 DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Adductor Spasmodic Dysphonia · Voice Disorders · Spasmodic Dysphonia
Primary: Our Primary Outcome is the Difference in VHI-10 Score at 30 Days After Injection With DAXI. — 17.81 units on a scale — p=<0.001
N/A N=12 Neuromodulation Therapy for Task-Specific Dystonia
Isolated Focal Hand Dystonia
Primary: Feasibility of Accurately Delivering TMS During the Task of Writing as Measured by Number of Participants Who Completed the TMS Sessions — 12; 12; 11 Participants
N/A N=38 Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
Dystonia-Parkinsonism, Adult-Onset · Parkinson Disease
Primary: Burke-Fahn-Marsden Dystonia Rating Scale — 3.5 units on a scale — p=<0.001
Phase 2 N=51 Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia
Cervical Dystonia
Primary: Number of Participants With Treatment-related Serious Adverse Events — 0; 0; 0 Participants
N/A N=9 Deep Brain Stimulation in Patients With Dystonia
Dystonia
Primary: The Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores Measured Before DBS Surgery (Baseline) and at 12 Months — 33.5 TWSTRS total score change